SG10201900025UA - Pyridines, pyrimidines, and pyrazines, as btk inhibitors and uses thereof - Google Patents

Pyridines, pyrimidines, and pyrazines, as btk inhibitors and uses thereof

Info

Publication number
SG10201900025UA
SG10201900025UA SG10201900025UA SG10201900025UA SG10201900025UA SG 10201900025U A SG10201900025U A SG 10201900025UA SG 10201900025U A SG10201900025U A SG 10201900025UA SG 10201900025U A SG10201900025U A SG 10201900025UA SG 10201900025U A SG10201900025U A SG 10201900025UA
Authority
SG
Singapore
Prior art keywords
pyrazines
pyridines
pyrimidines
uses
btk inhibitors
Prior art date
Application number
SG10201900025UA
Inventor
Lesley Liu-Bujalski
Ngan Nguyen
Hui Qiu
Reinaldo Jones
Igor Mochalkin
richard d Caldwell
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US201361860401P priority Critical
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of SG10201900025UA publication Critical patent/SG10201900025UA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y02A50/38Medical treatment of vector-borne diseases characterised by the agent
    • Y02A50/398Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a bacteria
    • Y02A50/399Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a bacteria of the genus Borrellia
    • Y02A50/401Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a bacteria of the genus Borrellia the bacteria being Borrelia burgdorferi, i.e. Lyme disease or Lyme borreliosis

Abstract

PYRIDINES, PYRIMIDINES, AND PYRAZINES, AS BTK INHIBITORS AND USES THEREOF The present invention relates to pyridine, pyrimidine, and pyrazene compounds, and pharmaceutically acceptable compositions thereof, useful as BTK inhibitors.
SG10201900025UA 2013-07-31 2014-07-30 Pyridines, pyrimidines, and pyrazines, as btk inhibitors and uses thereof SG10201900025UA (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US201361860401P true 2013-07-31 2013-07-31

Publications (1)

Publication Number Publication Date
SG10201900025UA true SG10201900025UA (en) 2019-02-27

Family

ID=51303133

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201900025UA SG10201900025UA (en) 2013-07-31 2014-07-30 Pyridines, pyrimidines, and pyrazines, as btk inhibitors and uses thereof
SG11201600159TA SG11201600159TA (en) 2013-07-31 2014-07-30 Pyridines, pyrimidines, and pyrazines, as btk inhibitors and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201600159TA SG11201600159TA (en) 2013-07-31 2014-07-30 Pyridines, pyrimidines, and pyrazines, as btk inhibitors and uses thereof

Country Status (22)

Country Link
US (2) US9738648B2 (en)
EP (1) EP3049417B1 (en)
JP (1) JP6612751B2 (en)
KR (1) KR20160036053A (en)
CN (1) CN105814057B (en)
AU (1) AU2014296261B2 (en)
CA (1) CA2918242A1 (en)
DK (1) DK3049417T3 (en)
ES (1) ES2706150T3 (en)
HR (1) HRP20190054T1 (en)
HU (1) HUE042111T2 (en)
IL (1) IL243844A (en)
LT (1) LT3049417T (en)
MX (1) MX367085B (en)
PL (1) PL3049417T3 (en)
PT (1) PT3049417T (en)
RS (1) RS58361B1 (en)
RU (1) RU2016106760A (en)
SG (2) SG10201900025UA (en)
SI (1) SI3049417T1 (en)
WO (1) WO2015017502A1 (en)
ZA (1) ZA201600564B (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
TWI659021B (en) 2013-10-10 2019-05-11 亞瑞克西斯製藥公司 Inhibitors of kras g12c
JP2018513853A (en) 2015-04-10 2018-05-31 アラクセス ファーマ エルエルシー Substituted quinazoline compounds and methods of use thereof
CA2982360A1 (en) 2015-04-15 2016-10-20 Liansheng Li Fused-tricyclic inhibitors of kras and methods of use thereof
US10144724B2 (en) 2015-07-22 2018-12-04 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
EA201891191A1 (en) 2015-11-16 2018-12-28 Араксис Фарма Ллк 2-substituted hinazolin compounds containing a substituted heterocyclic group and methods of their application
CN107021963A (en) 2016-01-29 2017-08-08 北京诺诚健华医药科技有限公司 Pyrazole fused ring analog derivative, its preparation method and its application in treating cancer, inflammation and immunity disease
US10266528B2 (en) * 2016-08-16 2019-04-23 Merck Patent Gmbh 2-oxo-imidazopyridines as reversible BTK inhibitors and uses thereof
EP3519402A1 (en) 2016-09-29 2019-08-07 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
US10377743B2 (en) 2016-10-07 2019-08-13 Araxes Pharma Llc Inhibitors of RAS and methods of use thereof
CN106831787B (en) * 2017-01-20 2018-10-23 成都倍特药业有限公司 Compound and its preparation method and application as bruton's tyrosine kinase inhibitor
WO2018140513A1 (en) * 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4650750A (en) 1982-02-01 1987-03-17 Giese Roger W Method of chemical analysis employing molecular release tag compounds
US4709016A (en) 1982-02-01 1987-11-24 Northeastern University Molecular analytical release tags and their use in chemical analysis
US5650270A (en) 1982-02-01 1997-07-22 Northeastern University Molecular analytical release tags and their use in chemical analysis
US5516931A (en) 1982-02-01 1996-05-14 Northeastern University Release tag compounds producing ketone signal groups
SU1212012A1 (en) * 1984-10-05 1996-03-20 Всесоюзный научно-исследовательский химико-фармацевтический институт им.Серго Орджоникидзе Derivatives of 4,5-dihydropirrolo[1,2,3-e,<d>] pteridine possessing antitumoral activity and method of obtaining the same
TW200519116A (en) * 2003-08-26 2005-06-16 Teijin Pharma Ltd Pyrrolopyrimidine derivatives
US20050080053A1 (en) * 2003-08-29 2005-04-14 Biocryst Pharmaceuticals, Inc. Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
WO2005118588A1 (en) * 2004-06-02 2005-12-15 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
BRPI0513982A (en) * 2004-07-30 2007-11-27 Methylgene Inc vegf receptor and hgf receptor signaling inhibitors
TW200740820A (en) * 2005-07-05 2007-11-01 Takeda Pharmaceuticals Co Fused heterocyclic derivatives and use thereof
TW200730527A (en) * 2005-12-02 2007-08-16 Takeda Pharmaceuticals Co Fused heterocyclic compound
EP2102170A2 (en) * 2006-12-06 2009-09-23 Boehringer Ingelheim International GmbH Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
BRPI0720169A2 (en) * 2006-12-12 2013-12-24 Takeda Pharmaceutical Compound or a salt thereof, product, pharmaceutical agent, method for prophylaxis or treatment of cancer and use of the compound
GB0708141D0 (en) * 2007-04-26 2007-06-06 Syngenta Participations Ag Improvements in or relating to organic compounds
AR070874A1 (en) * 2008-03-12 2010-05-12 Takeda Pharmaceutical Fused heterocyclic compound, a pharmaceutical composition comprising it and its use in treating cancer.
WO2010036910A1 (en) * 2008-09-26 2010-04-01 Yoshikazu Ohta Heart protection by administering an amp-activated protein kinase activator
HUE028672T2 (en) * 2009-10-08 2016-12-28 Merck Sharp & Dohme Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
KR101483215B1 (en) * 2010-01-29 2015-01-16 한미약품 주식회사 Bicyclic heteroaryl derivatives having inhibitory activity for protein kinases
WO2012150866A1 (en) * 2011-05-03 2012-11-08 Industrial Research Limited Phosphoribosyltransferase inhibitors and uses thereof
AU2012255792A1 (en) * 2011-05-17 2013-11-07 Principia Biopharma Inc. Azaindole derivatives as tyrosine kinase inhibitors
US9376438B2 (en) * 2011-05-17 2016-06-28 Principia Biopharma, Inc. Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
ES2708224T3 (en) * 2011-07-19 2019-04-09 Merck Sharp & Dohme 4-Imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as inhibitors of Btk
EP2548877A1 (en) * 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
CN103874699A (en) * 2011-09-20 2014-06-18 赛尔佐姆有限公司 Pyrazolo[4,3-c]pyridine derivatives as kinase inhibitors

Also Published As

Publication number Publication date
US20160159804A1 (en) 2016-06-09
CN105814057A (en) 2016-07-27
JP6612751B2 (en) 2019-11-27
HUE042111T2 (en) 2019-06-28
ES2706150T3 (en) 2019-03-27
KR20160036053A (en) 2016-04-01
WO2015017502A1 (en) 2015-02-05
DK3049417T3 (en) 2019-01-14
RS58361B1 (en) 2019-03-29
LT3049417T (en) 2019-02-11
MX2016001146A (en) 2016-04-29
IL243844A (en) 2019-10-31
JP2016531119A (en) 2016-10-06
PL3049417T3 (en) 2019-03-29
US20170226113A1 (en) 2017-08-10
PT3049417T (en) 2019-01-24
ZA201600564B (en) 2019-04-24
CA2918242A1 (en) 2015-02-05
SG11201600159TA (en) 2016-02-26
CN105814057B (en) 2019-05-03
RU2016106760A (en) 2017-09-04
HRP20190054T1 (en) 2019-02-22
US9738648B2 (en) 2017-08-22
EP3049417A1 (en) 2016-08-03
US10005784B2 (en) 2018-06-26
SI3049417T1 (en) 2019-03-29
EP3049417B1 (en) 2018-10-17
IL243844D0 (en) 2016-04-21
MX367085B (en) 2019-08-05
AU2014296261B2 (en) 2018-11-15
AU2014296261A1 (en) 2016-02-11

Similar Documents

Publication Publication Date Title
JO3314B1 (en) Novel Amino Pyrimidine Derivatives
PH12015501483B1 (en) Heterocyclic compounds and uses thereof
MX2014007269A (en) Pyridinone and pyrimidinone derivatives as factor xia inhibitors.
MX2016004927A (en) Compositions useful for treating disorders related to kit.
PH12016500739A1 (en) Inhibitors of the fibrolast growth factor receptor
LT3057943T (en) Pyrimidine fgfr4 inhibitors
IL252036D0 (en) Pyrimidine or pyridine compounds, preparation method therefor and pharmaceutical uses thereof
PH12014501595A1 (en) Substituted annulated pyrimidines and triazines, and use thereof
PL3060563T3 (en) Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
MX2014005955A (en) Combination formulation of two antiviral compounds.
DK3019496T3 (en) Pyrimidine derivatives as kinase inhibitors
HK1213883A1 (en) Substituted pyrimidinyl and pyridinyl-pyrrolopyridinones, process for their preparation and their use as kinase inhibitors
MX2014008071A (en) Fused tetra or penta-cyclic pyridophthalazinones as parp inhibitors.
EP3097078A4 (en) Pyridines and pyrimidines and use thereof
IL244276D0 (en) Derivatives of pyrimidinone, pyridazinone, pyridinone or triazinones , pharmaceutical compositions comprising them and uses thereof
AU2015207757A8 (en) N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of SHP2
PH12015500263B1 (en) New bicyclic derivatives
IL245345D0 (en) Pyridine, pyrazine and pyridazine derivatives, their preparation and pharmaceutical compositions containing them
SG192946A1 (en) Solid forms of 3-(5-amino-2methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses
MX2014015049A (en) New diazaspirocycloalkane and azaspirocycloalkane.
AU2015237050A8 (en) Quinoline derivatives as SMO inhibitors
EP2968357A4 (en) S-imino-s-oxo iminothiazine compounds as bace inhibitors, compositions, and their use
IL240195D0 (en) Pyridone amide compounds, compositions comprising same and uses thereof
MX2015012334A (en) Methods and compositions for weed control.
MX2016015093A (en) Boronic acid derivatives and therapeutic uses thereof.